Barr Gets FDA Green Light For Allegra-D Amid Patent Dispute
The move would give Barr the right to make a generic version of the 12-hour 60mg and 120 mg extended-release tablets if the company prevails in a patent challenge against the French drug maker.
Barr is the first applicant to file an abbreviated New Drug Application containing a paragraph IV patent challenge on the patents relating to the Allegra-D...
Already a subscriber? Click here to login